StocksTelegraph
S&P 500—NASDAQ—DOW—RUSSELL—
NASDAQ · LENZ·Healthcare

LENZ Therapeutics, Inc. Stock Analysis & AI Score

LENZ Therapeutics, Inc. (LENZ) has an ST Score of 46.4 (C+), driven by its Financial Strength (A+) and held back by its Momentum (D-). Analysts rate it Buy with a $5.00 price target (+56.7% upside).

Market Open
$3.19
Prev Close
—
Market Cap
—
Day Range
—
52W Range
—
P/E
—
EPS (TTM)
—
Volume
—
Avg —
Beta
—
46
ST Score
46.4/100C+

Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.

As of

AI Daily Briefing

Analysis by AI

LENZ Stock Price History

—

LENZ Technical Indicators

FMP

Earnings Surprises

Analyst Forecast

Revenue Mix

Company Information

Employees—
CEO—
SectorHealthcare
IndustryBiotechnology
IPO Date—
Website—
Country—
ExchangeNASDAQ

SEC Filings

Annual Report (10-K)

Filing DateAcceptedLink
Loading…

Quarterly Report (10-Q)

Filing DateAcceptedLink
Loading…

Analyst Price Target

ESG Score

LENZ Latest Stock News

ST Score

LENZ
46.4out of 100
Grade C+

LENZ Therapeutics, Inc. (LENZ) has an ST Score of 46.4 (C+), driven by its Financial Strength (A+) and held back by its Momentum (D-). Analysts rate it Buy with a $5.00 price target (+56.7% upside).

Strongest
Financial StrengthA+
Weakest
MomentumD-
All factor grades
  • Financial StrengthA+
  • ForecastA-
  • GrowthB
  • ProfitabilityC
  • ValuationD+
  • MomentumD-
  • Piotroski2/9
Score methodology

Press Releases

Company Contact Details

LENZ stock: frequently asked questions

What is LENZ's ST Score?

LENZ Therapeutics, Inc. (LENZ) has an ST Score of 46.4 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Is LENZ a buy, hold, or sell?

Analysts rate LENZ a Buy, with a price target of $5.00 (+56.7% vs the current price). Our ST Score grades it C+ (46.4/100). The ST Score is a data-driven signal, not a recommendation.

What are LENZ's factor grades?

Valuation D+, Profitability C, Financial Strength A+, Momentum D-, Growth B, Forecast A-.

What is LENZ's valuation grade?

LENZ Therapeutics, Inc. (LENZ) earns a valuation grade of D+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

What is LENZ's growth grade?

LENZ Therapeutics, Inc. (LENZ) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

What is LENZ's profitability grade?

LENZ Therapeutics, Inc. (LENZ) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

What is LENZ's financial strength grade?

LENZ Therapeutics, Inc. (LENZ) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

What is the analyst price target for LENZ?

The average analyst price target for LENZ Therapeutics, Inc. (LENZ) is $5.00 from 5 analysts, which is +56.7% versus the recent price of $3.19.

What is LENZ's Piotroski score?

LENZ Therapeutics, Inc. (LENZ) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.